Key result
Metformin and other insulin-sensitizing drugs may benefit patients with polycystic ovary syndrome by improving hyperandrogenemia, hyperinsulinemia, and reducing risks of miscarriage and comorbidities.
Why the study?
Does metformin improve metabolic and cardiovascular risk profiles in patients with polycystic ovary syndrome?
Does metformin improve metabolic and cardiovascular risk profiles in patients with polycystic ovary syndrome?
Metformin may offer benefits in PCOS beyond ovulation induction, potentially reducing the risk of coronary artery disease, gestational diabetes, and obesity.
Supports metformin adjunctively in PCOS IVF; leaves open miscarriage reduction without randomized confirmation.
The debate on metformin use in polycystic ovary syndrome (PCOS) has mainly focused on its treatment for infertility in ovulation induction and menstrual cyclicity. Here we will summarize the data supporting the effect of metformin on improving hyperandrogenaemia and hyperinsulinaemia in PCOS patients. We propose that metformin benefits PCOS patients undergoing gonadotrophin therapy and IVF as well as ovulation induction. We also advocate the use of insulin sensitizing drugs to reduce miscarriage rates, and risks associated with coronary artery disease, gestational diabetes and obesity.
No takes yet. Share an insight, caveat, or question.
L. A. Stadtmauer (2002) conducted a review in Polycystic ovary syndrome (PCOS). Metformin and insulin sensitizing drugs was evaluated. Metformin and other insulin-sensitizing drugs may benefit patients with polycystic ovary syndrome by improving hyperandrogenemia, hyperinsulinemia, and reducing risks of miscarriage and comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: